Dietary Supplements

Industry Experts Will Spotlight Emerging Trends in OTCs, Dietary Supplements, and Consumer Medical Devices

The Consumer Healthcare Products Association released the following statement in response to the U.S. Food and Drug Administration report to Congress on the current cannabidiol marketplace.

CHPA is rebranding its identity for the first time in 20 years. The rebranding effort has resulted in a new logo, tagline, and brand narrative following the addition of consumer medical devices to its scope of representation.

The U.S. dietary supplement industry commends FDA for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19.

In this newly created role, Dr. Troup will lead strategy development and direct CHPA’s work on dietary supplements issues, evaluating science, shaping policy, and collaborating with stakeholders for this important, growing consumer health category.

The types of evidence used to monitor dietary supplement safety, including adverse event reports, emergency room visits and poison control center data.

The four leading trade associations representing the dietary supplement industry are concerned that some marketers of dietary supplements may be promoting them with claims of prevention or treatment of Coronavirus.

CHPA today applauds the U.S. Food and Drug Administration for enforcing existing provisions in the Federal Food, Drug, and Cosmetic Act by sending warning letters to 15 companies illegally marketing cannabidiol products.